Shares of Zydus Lifesciences Ltd are trading flat despite touching a day’s high of Rs 1,043.50 on 16th September, as the company announced that ZyVet Animal Health, a subsidiary of Zydus Pharmaceuticals (USA) Inc. and part of Zydus Lifesciences Ltd, has launched two FDA-approved generic medicines for animals in the United States.

Zydus Lifesciences’ US arm has launched two FDA-approved generic medicines for pets.

The first is phenylpropanolamine hydrochloride tablets to treat urinary incontinence in dogs, a condition often seen in older or spayed females. This launch offers veterinarians a more affordable option for long-term care.

The second is furosemide tablets for dogs and cats to manage congestive heart failure and chronic fluid retention. Furosemide is a common diuretic used to reduce swelling and lung congestion from heart, kidney, or other diseases.

Zydus said these generics will help vets provide reliable treatment while keeping costs lower for pet owners.

At 12:20 PM, the shares of Zydus Lifesciences were trading 0.082% lower at Rs 1,036.05 on NSE.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!